WO2023020523A1 - Dérivés bicycliques et leur utilisation - Google Patents

Dérivés bicycliques et leur utilisation Download PDF

Info

Publication number
WO2023020523A1
WO2023020523A1 PCT/CN2022/112931 CN2022112931W WO2023020523A1 WO 2023020523 A1 WO2023020523 A1 WO 2023020523A1 CN 2022112931 W CN2022112931 W CN 2022112931W WO 2023020523 A1 WO2023020523 A1 WO 2023020523A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
membered
haloc
stereoisomer
pharmaceutically acceptable
Prior art date
Application number
PCT/CN2022/112931
Other languages
English (en)
Inventor
Hongwei Yang
Cunbo Ma
Panliang GAO
Huifeng HAN
Peng Wang
Runze LI
Xiaoyu Liu
Yanping Wang
Wei LONG
Wei Zhang
Original Assignee
Jacobio Pharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co., Ltd. filed Critical Jacobio Pharmaceuticals Co., Ltd.
Publication of WO2023020523A1 publication Critical patent/WO2023020523A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the invention relates to compounds that inhibit the activity of multiple forms of K-Ras protein including K-Ras wild type and K-Ras mutant types, compositions comprising the same, and the methods of using the same.
  • K-Ras Kirsten Rat Sarcoma 2 Viral Oncogene Homolog
  • GDP-bound inactive
  • GTP-bound active
  • Aberrant expression of K-Ras accounts for up to ⁇ 20%of all cancers and oncogenic K-Ras mutations that stabilize GTP binding and lead to constitutive activation of K-Ras.
  • K-Ras mutations at codons 12, 13, 61 and other positions of the K-Ras primary amino acid sequence are present in 88%of all pancreatic adenocarcinoma patients, 50%of all colorectal adenocarcinoma patients, and 32%lung adenocarcinoma patients.
  • a recent publication also suggested wild type K-Ras inhibition could be a viable therapeutic strategy to treat K-Ras wild type dependent cancers.
  • Allele-specific K-Ras G12C inhibitors such as sotorasib (AMG510) or adagrasib (MRTX849) , are currently changing the treatment paradigm for patients with K-Ras G12C mutated non-small cell lung cancer and colorectal cancer.
  • sotorasib AMG510
  • MRTX849 adagrasib
  • K-Ras inhibitors have the potential to address broad patient populations, including K-Ras G12C, K-Ras G12D, K-Ras G12V, K-Ras G13D, K-Ras G12R, K-Ras G12S, K-Ras G12A, K-Ras Q61H mutant and K-Ras wild type amplified cancers.
  • a compound of formula (I) to formula (III) a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof or a conjugated form thereof:
  • composition comprising a therapeutically effective amount of a compound of formula (I) to formula (III) , a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof or a conjugated form thereof as defined herein; and a pharmaceutically acceptable excipient.
  • Also provided herein is a method for treating cancer in a subject comprising administering a therapeutically effective amount of a compound of formula (I) to formula (III) , a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof, a conjugated form thereof, or a pharmaceutical composition as defined herein to a subject in need thereof.
  • Also provided herein is a use of a compound of formula (I) to formula (III) , a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof, a conjugated form thereof, or a pharmaceutical composition as defined herein for the manufacture of a medicament for the treatment of cancer.
  • Also provided herein is a process for preparing a compound of formula (I) to formula (III) as defined herein.
  • a compound of formula (I) to formula (III) a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof or a conjugated form thereof:
  • R 1 is selected from
  • R 11 is selected from hydrogen, -C 1-6 alkyl, 3-6 membered cycloalkyl, 3-6 membered hetrocycloalkyl, phenyl, or 5-6 membered heteroaryl; wherein said -C 1-6 alkyl, 3-6 membered cycloalkyl, 3-6 membered hetrocycloalkyl, phenyl, or 5-6 membered heteroaryl is optionally independently substituted with one or more substituents selected from halogen, -C 1-3 alkyl;
  • n 1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10
  • m 2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; provided that m 1 and m 2 is not 0 at the same time;
  • n 1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10
  • n 2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10
  • n 3 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10
  • n 4 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10
  • n 5 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
  • p 1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10
  • p 2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; provided that p 1 and p 2 is not 0 at the same time;
  • p 3 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10
  • p 4 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; provided that p 3 and p 4 is not 0 at the same time;
  • t 1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10
  • t 2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; provided that t 1 and t 2 is not 0 at the same time;
  • t 3 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10
  • t 4 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; provided that t 3 and t 4 is not 0 at the same time;
  • each of rings is independently optionally substituted with one or more R 1a ;
  • Each of R 1a is independently selected from halogen, -C 1-6 alkyl, haloC 1-6 alkyl, -CN, oxo, -OH, -NH 2 , -NH (C 1-6 alkyl) , -NH (C 1-6 alkyl) 2 , -OC 1-6 alkyl, or -C 1-6 alkyl substituted with 1, 2 or 3 substituents selected form halogen, haloC 1-6 alkyl, -CN, -OH, -NH 2 , -NH (C 1-6 alkyl) , -NH (C 1-6 alkyl) 2 , -OC 1-6 alkyl or cyclopropyl;
  • Each of (q 11 , q 12 , q 13 , q 14 and q 15 ) is independently selected from 0, 1, 2, 3, 4, 5 or 6;
  • R 2 is selected from -L 20 - (3-12 membered heterocyclyl) , -L 20 - (3-12 membered cycloalkyl) , -L 20 - (6-12 membered aryl) , -L 20 - (5-12 membered heteroaryl) , -L 20 -N (R 2b ) 2 ,
  • Each of L 20 at each occurrence is independently selected from a bond or C 1-10 alkylene optionally substituted with one or more R Z21 ;
  • Said 3-12 membered heterocyclyl in -L 20 - (3-12 membered heterocyclyl) is optionally substituted with one or more R Z22 ;
  • Said 3-12 membered cycloalkyl in -L 20 - (3-12 membered cycloalkyl) is optionally substituted with one or more R Z22 ;
  • Said 6-12 membered aryl in -L 20 - (6-12 membered aryl) is optionally substituted with one or more R Z22 ;
  • Said 5-12 membered heteroaryl in -L 20 - (5-12 membered heteroaryl) is optionally substituted with one or more R Z22 ;
  • L 21 is selected from a bond or C 1-10 alkylene optionally substituted with one or more R Z23 ;
  • Ring B or ring C is a 3-10 membered heterocyclic ring optionally further containing 1, 2, or 3 heteroatoms selected from N, O or S;
  • two R S21 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 membered carbocylic ring or 3-10 heterocyclic ring is optionally substituted with one or more R Z24 ;
  • R S21 together with the carbon atoms to which they are respectively attached form a 3-10 membered carbocyclic ring, a 3-10 membered heterocyclic ring, a 6-10 membered aryl ring or a 5-10 membered heteroaryl ring, wherein, each of rings is independently optionally substituted with one or more R Z25 ;
  • q 21 is selected from 0, 1, 2, 3, 4, 5 or 6;
  • L 22 is selected from a bond or C 1-10 alkylene optionally substituted with one or more R Z27 ;
  • Ring D is selected from a 3-10 membered carbocyclic ring or a 3-10 membered heterocyclic ring; wherein the moiety of -L 22 -and -L 23 -X 2 are attached to the same atom or different atoms of the ring D;
  • L 23 is selected from a bond or C 1-10 alkylene optionally substituted with one or more R Z28 ;
  • X 2 is selected from -N (R 25 ) 2 , -OR 25 , -SR 25 , 3-10 membered heterocyclyl, or 5-10 membered heteroaryl, wherein said 3-10 membered heterocyclyl or 5-10 membered heteroaryl is optionally independently substituted with one or more R Z29 ;
  • q 22 is selected from 0, 1, 2, 3, 4, 5 or 6;
  • R 4 is selected from 6-10 membered aryl, 5-10 membered heteroaryl, wherein said 6-10 membered aryl, 5-10 membered heteroaryl, is optionally independently substituted with one or more R S4 ;
  • Z at each occurrence is independently selected from C or N;
  • Ring E at each occurrence is independently selected from a 6 membered aryl ring or a 5-6 membered heteroaryl ring and ring F at each occurrence is a 3-10 membered carbocyclic ring or a 3-10 membered heterocyclic ring when Z is selected from C;
  • Ring E at each occurrence is selected from a 5-6 membered heteroaryl ring and ring F at each occurrence is a 3-10 membered heterocyclic ring when Z is selected from N;
  • each of (two R 21 , two R 23 , two R 25 , two R 26 , two R 28 , two R 31 , two R 33 , two R 41 , two R 43 , two R 61 , and two R 63 ) independently together with the nitrogen atom to which they are both attached forms a 3-20 membered heterocyclic ring or a 5-10 membered heteroaryl ring, wherein, said 3-20 membered heterocyclic ring or 5-10 membered heteroaryl ring is optionally independently substituted with one or more R Za ;
  • Each of (R 22 , R 24 , R 27 , R 29 , R 32 , R 34 , R 42 , R 44 , R 62 and R 64 ) at each occurrence is independently selected from hydrogen, -C 1-10 alkyl, haloC 1-10 alkyl, haloC 1-10 alkoxy, -C 2-10 alkenyl, haloC 2-10 alkenyl, -C 2-10 alkynyl, haloC 2-10 alkynyl, -N (R b ) 2 , -OR b , -SR b , 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered cycloalkynyl, 3-10 membered heterocyclyl, 6-10 membered aryl or 5-10 membered heteroaryl; wherein said -C 1-10 alkyl, haloC 1-10 alkyl, haloC 1-10 alkoxy, -C
  • Each of (R a , R b , R c , R d , R 2a and R 2b ) at each occurrence is independently selected from hydrogen, -C 1- 6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkenyl, 3-6 membered cycloalkynyl, 3-6 membered heterocyclyl, 6-10 membered aryl or 5-10 membered heteroaryl; wherein said -C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkenyl, 3-6 membered cycloalkynyl, 3-6 member
  • each of (two R a , two R b , two R c , two R 2a and two R 2b ) independently together with the atom to which they are both attached forms a 3-6 membered heterocyclic ring, wherein said 3-6 membered heterocyclic ring is independently optionally substituted with one or more R Zc ;
  • Each of heteroaryl at each occurrence is independently contain 1, 2, 3 or 4 heteroatoms selected from N, O, S.
  • n 1 is selected from 0, 1, 2, 3, 4, or 5
  • m 2 is selected from 0, 1, 2, 3, 4, or 5; provided that m 1 and m 2 is not 0 at the same time;
  • t 3 is selected from 0, 1, or 2; t 4 is selected from 0, 1, or 2; provided that t 3 and t 4 is not 0 at the same time.
  • each of R S11 at each occurrence is independently selected from -F, -Cl, -C 1-3 alkyl, haloC 1-3 alkyl, haloC 1-3 alkoxy, -C 2- 3 alkenyl, -C 2-3 alkynyl, -CN, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , -OH, -O (C 1-3 alkyl) , 3-6 membered cycloalkyl, 3-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein said -C 1-3 alkyl,
  • two R S11 together with the carbon atom to which they are both attached form a 3-6 membered carbocyclic ring or a 3-6 heterocyclic ring;
  • R S11 together with the carbon atoms to which they are respectively attached or form a 3-6 membered carbocyclic ring, a 3-6 membered heterocyclic ring, a phenyl ring or a 5-6 membered heteroaryl ring, wherein, each of rings is independently optionally substituted with one or more R 1a ;
  • Each of R 1a is independently selected from -F, -Cl, -C 1-3 alkyl, haloC 1-3 alkyl, -CN, -OH, -NH 2 , -NH (C 1- 3 alkyl) , -NH (C 1-3 alkyl) 2 , -OC 1-3 alkyl, or -C 1-3 alkyl substituted with 1, 2 or 3 substituents selected form -F, -Cl, haloC 1-3 alkyl, -CN, -OH, -NH 2 , -NH (C 1-3 alkyl) , -NH (C 1-3 alkyl) 2 , -OC 1-3 alkyl or cyclopropyl;
  • Each of (R S12 , R S13 , R S14 and R S15 ) at each occurrence is independently selected from -F, -Cl, -C 1-3 alkyl, haloC 1-3 alkyl, haloC 1-3 alkoxy, -C 2-3 alkenyl, -C 2-3 alkynyl, -CN, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , -OH, -O (C 1-3 alkyl) , 3-6 membered cycloalkyl, 3-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;
  • Each of (q 11 , q 12 , q 13 , q 14 and q 15 ) is independently selected from 0, 1, 2, or 3.
  • R 2 is selected from
  • L 21 is selected from a bond, C 1-3 alkylene, or C 1-3 alkylene substituted with 1 or 2 substituents selected from -F, -Cl, -C 1-3 alkyl, 3-6 membered cycloalkyl or 3-6 membered heterocyclyl;
  • L 22 is selected from a bond, C 1-3 alkylene, or C 1-3 alkylene substituted with 1 or 2 substituents selected from -F, -Cl, -C 1-3 alkyl, 3-6 membered cycloalkyl or 3-6 membered heterocyclyl;
  • L 23 is selected from a bond, C 1-3 alkylene or C 1-3 alkylene substituted with 1 or 2 substituents selected from -F, -Cl, -C 1-3 alkyl, 3-6 membered cycloalkyl or 3-6 membered heterocyclyl;
  • Ring B or ring C is a 5-6 membered heterocyclic ring optionally further containing 1 or 2 heteroatoms selected from N or O;
  • Ring D is a 3 membered carbocyclic ring; wherein the moiety of -L 22 -and -L 23 -X 2 are attached to the same atom or different atoms of the ring E;
  • X 2 is a 6 membered heterocyclyl, wherein said 3-6 membered heterocyclyl is optionally independently substituted with 1, 2 or 3 R Z29 .
  • q 21 is selected from 1, 2, 3 or 4.
  • Each of R 4b is independently selected from -F; -C 1-3 alkyl; haloC 1-3 alkyl; -CN; -OH; -NH 2 ; -NH (C 1-3 alkyl) ; -NH (C 1-3 alkyl) 2 ; -OC 1-3 alkyl; or -C 1-3 alkyl substituted with 1, 2 or 3 substituents selected form -F, haloC 1- 3 alkyl, -CN, -OH, -NH 2 , -NH (C 1-3 alkyl) , -NH (C 1-3 alkyl) 2 , -OC 1-3 alkyl or cyclopropyl.
  • the prodrug moiety is -OR 4a , and R 4a is selected from
  • R 4c is selected from hydrogen, -C 1-30 alkyl, -C 2-30 alkenyl, -C 2-30 alkynyl, -C 0-6 alkylene- (3-20 membered carbocyclyl) , -C 0-6 alkylene- (3-20 membered heterocyclyl) , -C 0-6 alkylene- (6-10 membered aryl) or -C 0- 6 alkylene- (5-10 membered heteroaryl) , each of which is independently substituted with one or more R 4j ;
  • R 5 is selected from hydrogen, -F, -Cl, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH (CH 3 ) 2 , -CN, -COOH, -CH 2 OH, -OH, -OCH 3 , -OCH 2 CH 3 , -CF 3 , -CHF 2 , -NH 2 , -NHCH 3 , -N (CH 3 ) 2 , -CH 2 NH 2 , -CH 2 CH 2 NH 2 , -CH 2 OH, -CH 2 CH 2 OH, -SH, -S-CH 3 , -S
  • R 5 is selected from hydrogen, -F, -Cl, -S-CH 3 , -S-CF 3 or and R 5 is selected from -H.
  • a pharmaceutical composition comprising a therapeutically effective amount of the compound of formula (I) to formula (III) , the stereoisomer thereof, the pharmaceutically acceptable salt thereof, the pharmaceutically acceptable salt of the stereoisomer thereof, the prodrug thereof, the deuterated molecule thereof or the conjugated form thereof of any one of [1] to [29] , and at least one pharmaceutically acceptable excipient.
  • a method for treating cancer in a subject comprising administering a therapeutically effective amount of the compound of formula (I) to formula (III) , the stereoisomer thereof, the pharmaceutically acceptable salt thereof, the pharmaceutically acceptable salt of the stereoisomer thereof, the prodrug thereof, the deuterated molecule thereof or the conjugated form thereof of any one of [1] to [29] , or the pharmaceutical composition of [30] to a subject in need thereof.
  • a method for treating cancer in a subject in need thereof comprising:
  • the cancer is associated with at least one of K-Ras G12C, K-Ras G12D, K-Ras G12V, K-Ras G13D, K-Ras G12R, K-Ras G12S, K-Ras G12A, K-Ras Q61H mutation and/or K-Ras wild type amplification.
  • halogen or “halo” , as used interchangeably herein, unless otherwise indicated, refers to fluoro, chloro, bromo or iodo.
  • the preferred halogen groups include -F, -Cl and -Br.
  • alkyl refers to saturated monovalent hydrocarbon radicals having straight or branched arrangement.
  • C 1-10 in -C 1-10 alkyl is defined to identify the group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in a linear or branched arrangement.
  • Non-limiting alkyl includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl and 2-methylpentyl.
  • haloalkyl refers to the above-mentioned alkyl substituted with one or more (for example 1, 2, 3, 4, 5, or 6) halogen (such as -F, -Cl or -Br) .
  • the haloalkyl is interchangeable -C 1-10 haloalkyl or haloC 1-10 alkyl, wherein, C 1-10 in the -C 1- 10 haloaklyl or haloC 1-10 alkyl indicates that the total carbon atoms of the alkyl are 1 to 10.
  • the -C 1-10 haloalkyl is the -C 1-6 haloalkyl.
  • the -C 1-6 haloalkyl is the -C 1- 3 haloalkyl.
  • the -C 1-3 haloalkyl is (methyl, ethyl, propyl or isopropyl) substituted with 1, 2, 3, 4, 5, or 6 -F; preferably, the -C 1-3 haloalkyl is -CF 3 .
  • alkylene refers to a divalent group obtained by removal of an additional hydrogen atom from an alkyl group defined above.
  • the alkylene is C 0-6 alkylene.
  • the C 0-6 alkylene is C 0-3 alkylene. The C 0-6 in the front of the alkylene indicates the total carbon atoms in the alkylene are 0 to 6 and C 0 indicates the two ends of the alkylene are connected directly.
  • Non-limiting alkylene includes methylene (i.e., -CH 2 -) , ethylene (i.e., -CH 2 -CH 2 -or -CH (CH 3 ) -) and propylene (i.e., -CH 2 -CH 2 -CH 2 -, -CH (-CH 2 -CH 3 ) -or -CH 2 -CH (CH 3 ) -) .
  • alkenyl refers to a straight or branch-chained hydrocarbon radical containing one or more double bonds and typically from 2 to 20 carbon atoms in length.
  • the alkenyl is -C 2-10 alkenyl.
  • the -C 2-10 alkenyl is -C 2-6 alkenyl which contains from 2 to 6 carbon atoms.
  • Non-limiting alkenyl includes ethenyl, propenyl, butenyl, 2-methyl-2-buten-1-yl, hepetenyl, octenyl and the like.
  • haloalkenyl refers to the above-mentioned alkenyl substituted with one or more (for example 1, 2, 3, 4, 5, or 6) halogen (such as -F, -Cl or -Br) .
  • the haloalkenyl is interchangeable -C 2-10 haloalkenyl or haloC 2-10 alkenyl, wherein, C 2-10 in the -C 2-10 haloaklenyl or haloC 2-10 alkenyl indicates that the total carbon atoms of the alkenyl are 2 to 10.
  • the -C 2-10 haloalkenyl is the -C 2-6 haloalkenyl. In some embodiments, the -C 2-6 haloalkenyl is the -C 2-3 haloalkenyl. In some embodiments, the -C 2-3 haloalkenyl is (ethenyl or propenyl) substituted with 1, 2, 3, 4, 5, or 6 -F.
  • alkynyl refers to a straight or branch-chained hydrocarbon radical containing one or more triple bonds and typically from 2 to 20 carbon atoms in length.
  • the alkynyl is -C 2-10 alkynyl.
  • the -C 2-10 alkynyl is -C 2-6 alkynyl which contains from 2 to 6 carbon atoms.
  • Non-limiting alkynyl includes ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
  • haloalkynyl refers to the above-mentioned alkynyl substituted with one or more (for example 1, 2, 3, 4, 5, or 6) halogen (such as -F, -Cl or -Br) .
  • the haloalkynyl is interchangeable -C 2-10 haloalkynyl or haloC 2-10 alkynyl, wherein, C 2-10 in the -C 2-10 haloaklynyl or haloC 2-10 alkynyl indicates that the total carbon atoms of the alkynyl are 2 to 10.
  • the -C 2-10 haloalkynyl is the -C 2-6 haloalkynyl. In some embodiments, the -C 2-6 haloalkynyl is the -C 2-3 haloalkynyl. In some embodiments, the -C 2-3 haloalkynyl is (ethynyl or propynyl) substituted with 1, 2, 3, 4, 5, or 6 -F.
  • alkoxy refers to oxygen ethers formed from the previously described alkyl groups.
  • haloalkoxy refers to the above-mentioned alkoxy substituted with one or more (for 1, 2, 3, 4, 5, or 6) halogen (-F, -Cl or -Br) .
  • the haloalkoxy is interchangeable -C 1-10 haloalkoxy or haloC 1-10 alkoxy.
  • the haloalkoxy is interchangeable -C 1-6 haloalkoxy or haloC 1-6 alkoxy, wherein, C 1-6 in the -C 1-6 haloakloxy or haloC 1-6 alkoxy indicates that the total carbon atoms of the alkoxy are 1 to 6.
  • the -C 1-6 haloalkoxy is the -C 1-3 haloalkoxy. In some embodiments, the -C 1-3 haloalkoxy is (methoxy, ethoxy, propoxy or isopropoxy) substituted with 1, 2, 3, 4, 5, or 6 -F; preferably, the -C 1-3 haloalkoxy is -OCF 3 .
  • carrier refers to a totally saturated or partially saturated monocyclic, bicyclic, bridged, fused, or spiro non-aromatic ring only containing carbon atoms as ring members.
  • carrier as used herein, unless otherwise indicated, means a monovalent group obtained by removal of a hydrogen atom on the ring carbon atom from the carbocyclic ring defined in the present invention.
  • the carbocyclic ring is interchangeable with the carbocyclyl ring in the present invention.
  • the carbocyclic ring is a three to twenty membered (such as 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, 15-, 16-, 17-, 18-, 19-or 20-membered) carbocyclic ring and is either fully saturated or has one or more degrees of unsaturation. Multiple degrees of substitution, for example, one, two, three, four, five or six, are included within the present definition.
  • the carbocyclic ring includes a cycloalkyl ring in which all ring carbon atoms are saturated, a cycloalkenyl ring which contains at least one double bond (preferred contain one double bond) , and a cycloalkynyl ring which contains at least one triple bond (preferred contain one triple bond) .
  • Cycloalkyl includes but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl and the like.
  • Cycloalkenyl includes but not limited to cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl and the like.
  • the carbocyclyl ring includes a monocyclic carbocyclyl ring, and a bicyclic or polycyclic carbocyclyl ring in which one, two or three or more atoms are shared between the rings.
  • the term “spirocyclic carbocyclic ring” refers to a carbocyclic ring in which each of the rings only shares one ring atom with the other ring.
  • the spirocyclic ring is bicyclic spirocyclic ring.
  • the spirocyclic carbocyclic ring includes a spirocyclic cycloalkyl ring and a spirocyclic cycloalkenyl ring and a spirocyclic cycloalkynyl ring.
  • the term “fused carbocyclic ring” refers to a carbocyclic ring in which each of the rings shares two adjacent ring atoms with the other ring.
  • the fused ring is a bicyclic fused ring.
  • the fused carbocyclic ring includes a fused cycloalkyl ring and a fused cycloalkenyl ring and a fused cycloalkynyl ring.
  • a monocyclic carbocyclic ring fused with an aromatic ring (such as phenyl) is included in the definition of the fused carbocyclic ring.
  • the term “bridged carbocyclic ring” refers to a carbocyclic ring that includes at least two bridgehead carbon ring atoms and at least one bridging carbon atom. In some embodiments, the bridged ring is bicyclic bridged ring.
  • the bridged carbocyclic ring includes a bicyclic bridged carbocyclic ring which includes two bridgehead carbon atoms and a polycyclic bridged carbocyclic ring which includes more than two bridgehead carbon atoms.
  • the bridged carbocyclic ring includes a bridged cycloalkyl ring, a bridged cycloalkenyl ring and a bridged cycloalkynyl ring.
  • Examples of monocyclic carbocyclyl and bicyclic carbocyclyl include but not limit to cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, and 1-cyclohex-3-enyl.
  • heterocyclic ring refers to a totally saturated or partially saturated monocyclic, bicyclic, bridged, fused, or spiro non-aromatic ring containing not only carbon atoms as ring members and but also containing one or more (such as 1, 2, 3, 4, 5, or 6) heteroatoms as ring members.
  • Preferred heteroatoms include N, O, S, N-oxides, sulfur oxides, and sulfur dioxides.
  • heterocyclyl as used herein, unless otherwise indicated, means a monovalent group obtained by removal of a hydrogen atom on the ring carbon atom or the ring heteroatom from the heterocyclic ring defined in the present invention.
  • the heterocyclic ring is interchangeable with the heterocyclyl ring in the present invention.
  • the heterocyclic ring is a three to twenty membered (such as 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, 15-, 16-, 17-, 18-, 19-or 20-membered) heterocyclic ring and is either fully saturated or has one or more degrees of unsaturation. Multiple degrees of substitution, for example, one, two, three, four, five or six, are included within the present definition.
  • the heterocyclic ring includes a heterocycloalkyl ring in which all ring carbon atoms are saturated, a heterocycloalkenyl ring which contains at least one double bond (preferred contain one double bond) , and a heterocycloalkynyl ring which contains at least one triple bond (preferred contain one triple bond) .
  • the heterocyclyl ring includes a monocyclic heterocyclyl ring, and a bicyclic or polycyclic heterocyclyl ring in which one, two or three or more atoms are shared between the rings.
  • the term “spirocyclic heterocyclic ring” refers to a heterocyclic ring in which each of the rings only shares one ring atom with the other ring.
  • the spirocyclic ring is bicyclic spirocyclic ring.
  • the spirocyclic heterocyclic ring includes a spirocyclic heterocycloalkyl ring and a spirocyclic heterocycloalkenyl ring and a spirocyclic heterocycloalkynyl ring.
  • the term “fused heterocyclic ring” refers to a heterocyclic ring in which each of the rings shares two adjacent ring atoms with the other ring.
  • the fused ring is a bicyclic fused ring.
  • the fused heterocyclic ring includes a fused heterocycloalkyl ring and a fused heterocycloalkenyl ring and a fused heterocycloalkynyl ring.
  • a monocyclic heterocyclic ring fused with an aromatic ring (such as phenyl) is included in the definition of the fused heterocyclic ring.
  • the term “bridged heterocyclic ring” refers to a heterocyclic ring that includes at least two bridgehead ring atoms and at least one bridging atom. In some embodiments, the bridged ring is bicyclic bridged ring.
  • the bridged heterocyclic ring includes a bicyclic bridged heterocyclic ring which includes two bridgehead atoms and a polycyclic bridged heterocyclic ring which includes more than two bridgehead atoms.
  • the bridged heterocyclic ring includes a bridged heterocycloalkyl ring, a bridged heterocycloalkenyl ring and a bridged heterocycloalkynyl ring.
  • heterocyclyl examples include but are not limited to azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxoazepinyl, azepinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone and oxadiazolyl.
  • aryl refers to a mono or polycyclic aromatic ring system only containing carbon ring atoms.
  • the preferred aryls are monocyclic or bicyclic 6-10 membered aromatic rings. Phenyl and naphthyl are preferred aryls.
  • heteroaryl refers to an aromatic ring containing carbons and one or more (such as 1, 2, 3 or 4) heteroatoms selected from N, O or S.
  • the heteroaryl may be monocyclic or polycyclic.
  • a monocyclic heteroaryl group may have 1 to 4 heteroatoms in the ring, while a polycyclic heteroaryl may contain 1 to 10 heteroatoms.
  • a polycyclic heteroaryl ring may contain fused ring junction, for example, bicyclic heteroaryl is a polycyclic heteroaryl.
  • Bicyclic heteroaryl rings may contain from 8 to 12 member atoms.
  • Monocyclic heteroaryl rings may contain from 5 to 8 member atoms (cabons and heteroatoms) , preferred monocyclic heteroaryl is 5 membered heteroaryl including 1, 2, 3 or 4 heteratomes selected from N, O or S, or 6 membered heteroaryl including 1 or 2 heteroatoms selected from N.
  • heteroaryl groups include, but not limited to thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyladeninyl, quinolinyl or isoquinolinyl.
  • one or more refers to one or more than one. In some embodiments, “one or more” refers to 1, 2, 3, 4, 5 or 6. In some embodiments, “one or more” refers to 1, 2, 3 or 4. In some embodiments, “one or more” refers to 1, 2, or 3. In some embodiments, “one or more” refers to 1 or 2. In some embodiments, “one or more” refers to 1. In some embodiments, “one or more” refers to 2. In some embodiments, “one or more” refers to 3. In some embodiments, “one or more” refers to 4. In some embodiments, “one or more” refers to 5. In some embodiments, “one or more” refers to 6.
  • substituted refers to a hydrogen atom on the carbon atom or a hydrogen atom on the nitrogen atom is replaced by a substituent.
  • substituents When one or more substituents are substituted on a ring in the present invention, it means that each of substituents may be respectively independently substituted on every ring atom of the ring including but not limited to a ring carbon atom or a ring nitrogen atom.
  • a ploycyclic ring such as a fused ring, a bridged ring or a sprio ring, each of substituents may be respectively independently substituted on every ring atom of the ploycyclic ring.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the present invention as the active ingredient as well as methods of preparing the instant compounds are also part of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.
  • pharmaceutically acceptable salt refers to a salt prepared from pharmaceutically acceptable non-toxic bases or acids.
  • pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases.
  • compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Since the compounds in the present invention are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60%pure, more suitably at least 75%pure, especially at least 98%pure (%are on a weight for weight basis) .
  • the present invention includes within its scope the prodrug of the compounds of this invention.
  • such prodrug will be functional derivatives of the compounds that are readily converted in vivo into the required compound.
  • the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs” , ed. H. Bundgaard, Elsevier, 1985.
  • the present invention includes all stereoisomers of the compound and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.
  • stereoisomer refers to an isomer in which atoms or groups of atoms in the molecule are connected to each other in the same order but differ in spatial arrangement, including conformational isomers and configuration isomers.
  • the configuration isomers include geometric isomers and optical isomers, and optical isomers mainly include enantiomers and diastereomers.
  • the invention includes all possible stereoisomers of the compound.
  • the present invention is intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include deuterium and tritium.
  • the isotopes of hydrogen can be denoted as 1 H (hydrogen) , 2 H (deuterium) and 3 H (tritium) . They are also commonly denoted as D for deuterium and T for tritium.
  • CD 3 denotes a methyl group wherein all of the hydrogen atoms are deuterium.
  • Isotopes of carbon include 13 C and 14 C.
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent.
  • deuterated derivative refers to a compound having the same chemical structure as a reference compound, but with one or more hydrogen atoms replaced by a deuterium atom ( “D” ) . It will be recognized that some variation of natural isotopic abundance occurs in a synthesized compound depending on the origin of chemical materials used in the synthesis. The concentration of naturally abundant stable hydrogen isotopes, notwithstanding this variation is small and immaterial as compared to the degree of stable isotopic substitution of deuterated derivative described herein.
  • the deuterated derivative of the disclosure have an isotopic enrichment factor for each deuterium atom, of at least 3500 (52.5%deuterium incorporation at each designated deuterium) at least 4500, (67.5 %deuterium incorporation) , at least 5000 (75%deuterium incorporation) at least 5500 (82.5%deuterium incorporation) , at least 6000 (90%deuterium incorporation) , at lease 6333.3 (95%deuterium incorporation, at least 6466.7 (97%deuterium incorporation, or at least 6600 (99%deuterium incorporation) .
  • the present invention includes any possible tautomer and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
  • conjugated form refers to herein that the compound described herein is conjugated to another agent through a linker or not through a linker, wherein, the compound functions as a binder or a inhibitor of K-Ras protein (including K-Ras G12C, K-Ras G12D, K-Ras G12V, K-Ras G13D, K-Ras G12R, K-Ras G12S, K-Ras G12A, K-Ras Q61H mutant protein and K-Ras wild type protein)
  • the conjugated form is a PROTAC molecule, e.g. the compound is incorporated into proteolysis targeting chimeras (PROTACs) .
  • a PROTAC is a bifunctional molecule, with one portion capable of engaging an E3 ubiquitin ligase, and the other portion having the ability to bind to a target protein meant for degradation by the cellular protein quality control machinery. Recruitment of the target protein to the specific E3 ligase results in its tagging for destruction (i.e., ubiquitination) and subsequent degradation by the proteasome. Any E3 ligase can be used.
  • the portion of the PROTAC that engages the E3 ligase is connected to the portion of the PROTAC that engages the target protein via a linker which consists of a variable chain of atoms.
  • variable chain of atoms can include, for example, rings, heteroatoms, and/or repeating polymeric units. It can be rigid or flexible. It can be attached to the two portions described above using standard techniques in the art of organic synthesis.
  • compositions of the present invention comprise a compound in present invention (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
  • the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • a compound of Formula (I) , (II) or (III) , a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof or a conjugated form thereof as defined herein can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous) .
  • the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as oil-in-water emulsion or as a water-in-oil liquid emulsion.
  • the compound in the present invention or a pharmaceutically acceptable salt thereof may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
  • compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt.
  • the compounds of the present invention or pharmaceutically acceptable salts thereof can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid or gas.
  • solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • liquid carriers are sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include carbon dioxide and nitrogen.
  • oral liquid preparations such as suspensions, elixirs and solutions
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets.
  • oral solid preparations such as powders, capsules and tablets.
  • tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques.
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
  • compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
  • the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , vegetable oils, and suitable mixtures thereof.
  • compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound in the present invention or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 0.05wt%to about 10wt%of the compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier (s) followed by chilling and shaping in molds.
  • the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient.
  • subject refers to an animal.
  • the animal is a mammal.
  • a subject also refers to for example, primates (e.g., humans) , cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like.
  • the subject is a human.
  • a “patient” as used herein refers to a human subject.
  • a subject is “in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
  • the subject has experienced and/or exhibited at least one symptom of cancer to be treated and/or prevented.
  • the subject has been identified or diagnosed as having a cancer having wild type K-Ras or a K-Ras G12A, K-Ras G12C, K-Ras G12D, K-Ras G12R, K-Ras G12S, K-Ras G12V, K-Ras G13D and/or K-Ras Q61H mutation
  • inhibitors refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • treat refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof) .
  • “treat” , “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat” , “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom) , physiologically, (e.g., stabilization of a physical parameter) , or both.
  • “treat” , “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
  • K-Ras G12A refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of an alanine for a glycine at amino acid position 12.
  • a “K-Ras G12A inhibitor” refers to a compound is capable of negatively modulating or inhibiting all or a portion of the function of K-Ras G12A.
  • a “K-Ras G12A associated cancer” as used herein refers to a cancer associated with or mediated by or having a K-Ras G12A mutation.
  • K-Ras G12C refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of a cysteine for a glycine at amino acid position 12.
  • a “K-Ras G12C inhibitor” refers to a compound is capable of negatively modulating or inhibiting all or a portion of the function of K-Ras G12C.
  • a “K-Ras G12C associated cancer” as used herein refers to a cancer associated with or mediated by or having a K-Ras G12C mutation.
  • K-Ras G12D refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of an aspartic acid for a glycine at amino acid position 12.
  • a “K-Ras G12D inhibitor” refers to a compound is capable of negatively modulating or inhibiting all or a portion of the function of K-Ras G12D.
  • a “K-Ras G12D associated cancer” as used herein refers to a cancer associated with or mediated by or having a K-Ras G12D mutation.
  • K-Ras G12R refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of an arginine for a glycine at amino acid position 12.
  • a “K-Ras G12R inhibitor” refers to a compound is capable of negatively modulating or inhibiting all or a portion of the function of K-Ras G12R.
  • a “K-Ras G12R associated cancer” as used herein refers to a cancer associated with or mediated by or having a K-Ras G12R mutation.
  • K-Ras G12S refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of a serine for a glycine at amino acid position 12.
  • a “K-Ras G12S inhibitor” refers to a compound is capable of negatively modulating or inhibiting all or a portion of the function of K-Ras G12S.
  • a “K-Ras G12S associated cancer” as used herein refers to a cancer associated with or mediated by or having a K-Ras G12S mutation.
  • K-Ras G12V refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of a valine for a glycine at amino acid position 12.
  • a “K-Ras G12V inhibitor” refers to a compound is capable of negatively modulating or inhibiting all or a portion of the function of K-Ras G12V.
  • a “K-Ras G12V associated cancer” as used herein refers to a cancer associated with or mediated by or having a K-Ras G12V mutation.
  • K-Ras G13D refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of an aspartic acid for a glycine at amino acid position 13.
  • a “K-Ras G13D inhibitor” refers to a compound is capable of negatively modulating or inhibiting all or a portion of the function of K-Ras G13D.
  • a “K-Ras G13D associated cancer” as used herein refers to a cancer associated with or mediated by or having a K-Ras G13D mutation.
  • K-Ras Q61H refers to a mutant form of a mammalian K-Ras protein that contains an amino acid substitution of a histidine for a glutamine at amino acid position 61.
  • a “K-Ras Q61H inhibitor” refers to a compound is capable of negatively modulating or inhibiting all or a portion of the function of K-Ras Q61H.
  • a “K-Ras Q61H associated cancer” as used herein refers to a cancer associated with or mediated by or having a K-Ras Q61H mutation.
  • the intermediates were synthesized using conventional preparation method.
  • Compound 3 (50 mg, 82.5595 ⁇ mol) was separated by Prep-HPLC-Gilson with the following conditions: Column, CHIRAL ART Cellulose-SC column (2 cm ⁇ 25 cm, 5 ⁇ m) ; mobile phase, Hex (0.1%IPA. M) /EtOH (60: 40) ; Flowing rate: 20 mL/min to give Compound 3A (17 mg, the first eluting isomer, Retention Time 8.044 min) and Compound 3B (8 mg, the second eluting isomer, Retention Time 9.262 min) respectively.
  • Compound 4 (34 mg, 56.5103 ⁇ mol) was separated by Prep-HPLC-Gilson with the following conditions: Column, CHIRAL ART Cellulose-SC column (2 cm ⁇ 25 cm, 5 ⁇ m) ; mobile phase, Hex (0.1%DEA) /EtOH (60: 40) ; Flowing rate: 20 mL/min to give Compound 4A (7 mg, the first eluting isomer, Retention Time 6.478 min) and Compound 4B (6 mg, the second eluting isomer, Retention Time 7.675 min) respectively.
  • Compound 30-1 was synthesized based on the same method as Compound 1-3 in Example 1, except that “azepane” in Example 1 is replaced with “4, 4-difluoroazepane hydrochloride” .
  • Compound 33-1 was synthesized based on the same method as Compound 1-1 in Example 1, except that “azepane” in Example 1 is replaced with “3-oxa-6-azabicyclo [3.1.1] heptane 4-methylbenzenesulfonate” .
  • Compound 34-1 was synthesized based on the same method as Compound 1-2 in Example 1, except that “azepane” in Example 1 is replaced with “ (1R, 4R) -2-oxa-5-azabicyclo [2.2.1] heptane” .
  • Compound 36-4 was synthesized based on the same method as Compound 1-4 in Example 1, except that “azepane” in Example 1 is replaced with “ (1R, 4R) -2-oxa-5-azabicyclo [2.2.1] heptane” .
  • Compound 61-4 was synthesized based on the same method as Compound 1-4 in Example 1, except that “azepane” in Example 1 is replaced with “8-oxa-3-azabicyclo [3.2.1] octane hydrochloride” .
  • Compound 62-4 was synthesized based on the same method as Compound 1-4 in Example 1, except that “azepane” in Example 1 is replaced with “3-oxa-6-azabicyclo [3.1.1] heptane 4-methylbenzenesulfonate” .
  • K-Ras G12D K-Ras G12V, K-Ras G12C, K-Ras G13D, K-Ras G12A, K-Ras G12R, K-Ras Q61H and K-Ras WT proteins were used in this assay.
  • K-Ras His tag, aa 1-169 pre-loaded with GDP was pre-incubated with each of compounds in the presence of 10 nM GDP in a 384-well plate (Greiner) for 15-60 mins, then purified SOS1 ExD (Flag tag, aa 564-1049) , BODIPY TM FL GTP (Invitrogen) and monoclonal antibody anti 6HIS-Tb cryptate Gold (Cisbio) were added to the assay wells and incubated for 4 hours at 25 °C (Specially, we did not add SOS1 in the K-Ras G13D assay) .
  • GppNp is an analog of GTP.
  • K-Ras G12D, K-Ras G12V, K-Ras G12C, K-Ras G13D, K-Ras G12A, K-Ras G12R, K-Ras Q61H and K-Ras WT proteins were used in this assay.
  • K-Ras His tag, aa 1-169 pre-loaded with GppNp was pre-incubated with each of compounds in the presence of 200 ⁇ M GTP in a 384-well plate (Greiner) for 15-60 mins, then cRAF RBD (GST tag, aa 50-132, CreativeBioMart) , monoclonal antibody anti GST-d2 (Cisbio) and monoclonal antibody anti 6HIS-Tb cryptate Gold (Cisbio) were added to the assay wells and incubated for 2 hours at 25 °C. Wells containing same percent of DMSO served as vehicle control, and wells without K-Ras served as low control.
  • MKN-1 with K-Ras WT amplification is also a K-Ras dependent cell line.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé représenté par la formule (I), (II) ou (III), un stéréoisomère de celui-ci, un sel pharmaceutiquement acceptable de celui-ci, un sel pharmaceutiquement acceptable dudit stéréoisomère.
PCT/CN2022/112931 2021-08-18 2022-08-17 Dérivés bicycliques et leur utilisation WO2023020523A1 (fr)

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/113365 2021-08-18
CN2021113365 2021-08-18
CNPCT/CN2021/120859 2021-09-27
CN2021120859 2021-09-27
CN2021123382 2021-10-12
CNPCT/CN2021/123382 2021-10-12
CNPCT/CN2021/123565 2021-10-13
CN2021123565 2021-10-13
CNPCT/CN2021/123604 2021-10-13
CN2021123604 2021-10-13
CNPCT/CN2021/124425 2021-10-18
CN2021124365 2021-10-18
CN2021124425 2021-10-18
CNPCT/CN2021/124365 2021-10-18
CNPCT/CN2021/139161 2021-12-17
CNPCT/CN2021/139170 2021-12-17
CN2021139161 2021-12-17
CN2021139170 2021-12-17
CNPCT/CN2022/081022 2022-03-15
CN2022081022 2022-03-15
CNPCT/CN2022/087374 2022-04-18
CN2022087374 2022-04-18

Publications (1)

Publication Number Publication Date
WO2023020523A1 true WO2023020523A1 (fr) 2023-02-23

Family

ID=85240060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/112931 WO2023020523A1 (fr) 2021-08-18 2022-08-17 Dérivés bicycliques et leur utilisation

Country Status (1)

Country Link
WO (1) WO2023020523A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172940A1 (fr) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Méthodes de traitement du cancer du poumon réfractaire immunitaire
CN117186095A (zh) * 2023-11-02 2023-12-08 南方科技大学 靶向kras蛋白g12d突变体的共价抑制剂
WO2023240263A1 (fr) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Inhibiteurs de ras macrocycliques
WO2024008068A1 (fr) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. Inhibiteurs de protéine mutante k-ras
WO2024012519A1 (fr) * 2022-07-13 2024-01-18 北京华森英诺生物科技有限公司 Inhibiteur de pan-kras
WO2024041606A1 (fr) * 2022-08-24 2024-02-29 泰励生物科技（上海）有限公司 Composé ayant une activité tumorale de mutant anti-kras
WO2024061333A1 (fr) * 2022-09-21 2024-03-28 甘李药业股份有限公司 Inhibiteur de protéine mutante kras, son procédé de préparation et son utilisation
WO2024112654A1 (fr) 2022-11-21 2024-05-30 Treeline Biosciences, Inc. Inhibiteurs de kras spirocycliques de dihydropyranopyrimidine
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations
WO2024211712A1 (fr) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras
WO2024211663A1 (fr) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041671A1 (fr) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d
WO2022031678A1 (fr) * 2020-08-04 2022-02-10 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d
WO2022042630A1 (fr) * 2020-08-26 2022-03-03 InventisBio Co., Ltd. Composés hétéroaryle, leurs procédés de préparation et leurs utilisations
WO2022061251A1 (fr) * 2020-09-18 2022-03-24 Plexxikon Inc. Composés et procédés pour la modulation de kras et leurs indications
WO2022132200A1 (fr) * 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Inhibiteurs pan-kras d'azaquinazoline
WO2022184178A1 (fr) * 2021-03-05 2022-09-09 Jacobio Pharmaceuticals Co., Ltd. Inhibiteurs de kras g12d
WO2022187528A1 (fr) * 2021-03-05 2022-09-09 Nikang Therapeutics, Inc Dérivés de quinazoline amine en tant qu'inhibiteurs de kras

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041671A1 (fr) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d
WO2022031678A1 (fr) * 2020-08-04 2022-02-10 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d
WO2022042630A1 (fr) * 2020-08-26 2022-03-03 InventisBio Co., Ltd. Composés hétéroaryle, leurs procédés de préparation et leurs utilisations
WO2022061251A1 (fr) * 2020-09-18 2022-03-24 Plexxikon Inc. Composés et procédés pour la modulation de kras et leurs indications
WO2022132200A1 (fr) * 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Inhibiteurs pan-kras d'azaquinazoline
WO2022184178A1 (fr) * 2021-03-05 2022-09-09 Jacobio Pharmaceuticals Co., Ltd. Inhibiteurs de kras g12d
WO2022187528A1 (fr) * 2021-03-05 2022-09-09 Nikang Therapeutics, Inc Dérivés de quinazoline amine en tant qu'inhibiteurs de kras

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY ANONYMOUS : "- 3-Azabicyclo[3.2.1]octan-6-ol, 3-[7-[8-ethyl-7-fluoro-3-(methoxymethoxy)-1- naphthalenyl]-8-fluoro-2-[[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin- 7a(5H)-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]- ", XP093037438, retrieved from STN *
DATABASE Registry ANONYMOUS : "6-Azaspiro[3.5]nonan-2-ol, 6-[7-[7,8-difluoro-3-(methoxymethoxy)-1- naphthalenyl]-8-fluoro-2-[[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin- 7a(5H)-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-", XP093037440, retrieved from STN *
DATABASE Registry STN; ANONYMOUS : "3,8-Diazabicyclo[3.2.1]octane-8-carboxylic acid, 3-[7-(8-chloro-1-naphthalenyl)-8-fluoro-2-[[(2R,7aS)-2-fluorotetrahydro-1H- pyrrolizin-7a(5H)-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-6-fluoro-, 1,1-dimethylethyl ester, rel-", XP093037436, Database accession no. 2622024-36-4 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172940A1 (fr) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Méthodes de traitement du cancer du poumon réfractaire immunitaire
WO2023240263A1 (fr) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Inhibiteurs de ras macrocycliques
WO2024008068A1 (fr) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. Inhibiteurs de protéine mutante k-ras
WO2024012519A1 (fr) * 2022-07-13 2024-01-18 北京华森英诺生物科技有限公司 Inhibiteur de pan-kras
WO2024041606A1 (fr) * 2022-08-24 2024-02-29 泰励生物科技（上海）有限公司 Composé ayant une activité tumorale de mutant anti-kras
WO2024061333A1 (fr) * 2022-09-21 2024-03-28 甘李药业股份有限公司 Inhibiteur de protéine mutante kras, son procédé de préparation et son utilisation
WO2024112654A1 (fr) 2022-11-21 2024-05-30 Treeline Biosciences, Inc. Inhibiteurs de kras spirocycliques de dihydropyranopyrimidine
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations
WO2024211712A1 (fr) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras
WO2024211663A1 (fr) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras
CN117186095A (zh) * 2023-11-02 2023-12-08 南方科技大学 靶向kras蛋白g12d突变体的共价抑制剂

Similar Documents

Publication Publication Date Title
WO2023020523A1 (fr) Dérivés bicycliques et leur utilisation
AU2022271425B2 (en) Processes of making and crystalline forms of a MDM2 inhibitor
WO2022184178A1 (fr) Inhibiteurs de kras g12d
WO2023020519A1 (fr) Dérivés de 1, 4-oxazépane et leurs utilisations
WO2023020521A1 (fr) Dérivés de pyrimidine fusionnée avec la pyridine et leur utilisation
WO2023046135A1 (fr) Dérivés de cycles condensés polycycliques et leur utilisation
CN112424188A (zh) 作为parp7抑制剂的哒嗪酮
WO2023020518A1 (fr) Dérivés de n-cyclopropylpyrido [4, 3-d] pyrimidin-4-amine et leurs utilisations
US20240308976A1 (en) Compounds that mediate protein degradation and uses thereof
KR20210052497A (ko) Mdm2 억제제의 제조 방법
NZ753956B2 (en) Processes of making and crystalline forms of a mdm2 inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22857834

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22857834

Country of ref document: EP

Kind code of ref document: A1